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Accepted 21 December 2009Human papilloma virus (HPV) infection is accepted as
an important viral infection in female. HPV infection is
confirmed for correlation with the oncogenesis [1]. The
infection has become the focus of interest in obstetricians
around the world. A long history of effect encountered with
this viral infection can be seen. Recently, the medical scien-
tists attained success in general HPV vaccine. HPV vaccine
becomes the hope for getting rid of cervical cancer, the most
important complication of chronic HPV infection [2e5].
Focusing on the HPV vaccination, because the HPV can be
generated by many serotypes, including HPV 6, 11, 16, and
18, therefore, the vaccine for coverage on all serotypes is the
standard vaccine at present [6e8]. The HPV vaccination is
proved useful in female. Although natural immunity can be
generated from natural infection, the level of immunity is very
low, not lifelong, and cannot protect from reinfection. There-
fore, the vaccination seems to be the best primary prevention.
In the present situation of economical crisis, the usage of HPV
vaccine should be focused on its utility. In this work, the
author hereby performs a cost utility analysis of HPVTable 1
Cost utility analysis of the HPV vaccination for females in three age groups
Age groups (yr) Cost (US$)a Utilityb
Efficacy (%)
<24 230 96
24e34 230 92
34e45 230 89
a The cost of HPV vaccination is set as the cost of the vaccine in its full course
b The utility is the finalized result from multiplication of efficacy and immunog
vaccination trails. Focusing on immunogenicity, the finalized average value from rep
and the reported value within age group “<24 years old” is set as referenced valu
c The cost utility can be calculated by “cost utility¼ cost/utility.”
HPV¼ human pappiloma virus.
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This work is a medical economics study. The cost utility
analysis is performed. The cost of HPV vaccination is set as the
cost of the vaccine in its full course. The utility is set based on
previous standard reports on HPV vaccination trials. The utility
in thiswork is assigned to twomain properties, which are general
studies in any HPV trials [9], namely, vaccine efficacy and
immunogenicity of thevaccine. The cost utility in this work is set
as the ratio between cost and utility for each studied age group.
In this work, the cost utility of the HPV vaccination for
females in three age groups (1) younger than 24 years old;
(2) 24e34 years old; and (3) 34e45 years old is performed.
The details on cost and utility for each age group is presented
in Table 1. It seems that the cost utility of the age group
“younger than 24 years old” is the lowest and that of the age
group “34e45 years old” is the highest.
Infection with HPV is confirmed as a precancerous stage.
The female genital tract cancer has strong relationship to
chronic HPV infection [1]. According to the concept ofCost utility (US$)c
Immunogenicity (%)
100 239.6
86.75 288.2
76 340.0
. The reference price from hospital in Bangkok Thailand is used.
enicity in each age group. The data is derived from standard reports on HPV
orted immunogenicity for each serotype 6, 11, 16, and 18 is used in calculation
e and set at 100%.
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vaccine is raised [2e5]. The quadrivalent HPV is accepted as
the vaccine that has best coverage on the problematic sero-
types of HPV [6e8]. Based on the pharmacoeconomics prin-
ciple, the evaluation on the medical economics aspect of the
new vaccine is required [10,11]. The cost effectiveness of the
vaccination is confirmed over the nonvaccination [10,11].
However, because the vaccine is expensive for developing
countries, application for all might be problematic and it needs
for priority ranking. The usage of HPV vaccination in three
different age groups is hereby studied. It is detected that the
cost per utility of vaccination increases by age. This means
that the prevention by vaccination is more economically
preferable in young female. This is also concordant with the
fact that the infection starts at younger age in females and
chronic infection occur and finalize its way on to cancer.
Indeed, a recent article by Jenson [12] also noted for a para-
digm shift to the early vaccination in childhood.
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